Related Experiment Videos
A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. A Gynecologic Oncology Group study
R E Slayton1, J A Blessing, D Clarke-Pearson
1Department of Medicine, Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.
Investigational New Drugs
|February 1, 1991
Abstract:
AZQ was given intravenously to 23 patients with mixed mesodermal sarcoma of the uterus refractory to conventional treatment at a dose of 22.5-30 mg/m2 q three weeks. There was one partial response lasting seven weeks and one drug-related death. Based upon the activity observed in this trial, there does not appear to be a significant role for AZQ as a salvage agent for mixed mesodermal sarcomas of the uterus at the dose and schedule tested.